Samyang Corporation
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Samyang Corporation
Stock Watch: Advanced Therapies Deliver Fourth-Quarter Flop
As drug pricing continues its ascent among hot button issues, the multi-million-dollar price tags for one-and-done advanced therapies, their justification and reimbursement all remain unaligned.
Asia Deal Watch: Ono Inks Partnerships With Switzerland’s Numab, US Biotech Shattuck
Plus alliances involving Xyphos/Kelonia, Nippon Shinyaku/Vicor, Telix/QSAM, Nicox/Kowa, Kyowa Kirin/BridgeBio, as well as deals in brief.
AstraZeneca’s Danicopan Among Four Orphans Up For EU Approval Decision
The European Medicines Agency is due to decide whether to back pan-EU marketing authorization for 11 new products, including four orphan drugs.
What’s Next? Five Things To Look Out For In January
Generics Bulletin previews the most noteworthy and anticipated events for January 2024.
Company Information
- Industry
- Diversified
- Contract Manufacturing Organization
- Other Names / Subsidiaries
-
- Samyang Holdings Biopharmaceuticals Division
- Samyang Biopharm USA, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice